Can differences in breast cancer utilities explain disparities in breast cancer care?

Journal of General Internal Medicine

Volumn 21, Issue 12, 2006, Pages 1253-1260

  Schleinitz, Mark D ^a,b   DePalo, Dina ^a   Blume, Jeffrey ^b   Stein, Michael ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Breast cancer; Decision analysis; Disparities; Quality of life; Utilities

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; HORMONE;

ADULT; AGING; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; HEALTH CARE UTILIZATION; HORMONAL THERAPY; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; METASTASIS; PATIENT CARE; QUALITY ADJUSTED LIFE YEAR; TREATMENT PLANNING;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; BREAST NEOPLASMS; DEMOGRAPHY; FEMALE; HORMONES; HUMANS; INCOME; LOGISTIC MODELS; MARITAL STATUS; MARKOV CHAINS; NEOPLASM STAGING; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, ESTROGEN; REGRESSION ANALYSIS; SOCIOECONOMIC FACTORS;

EID: 33750507928     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1111/j.1525-1497.2006.00609.x     Document Type: Article

References (56)

1. Jazieh AR, Buncher CR. Racial and age-related disparities in obtaining screening mammography: results of a statewide database. South Med J. 2002;95:1145-8.
2. Peek ME, Han JH. Disparities in screening mammography. Current status, interventions and implications. J Gen Intern Med. 2004;19:184-94.
3. Pearlman DN, Rakowski W, Ehrich B, Clark MA. Breast cancer screening practices among black, Hispanic, and white women: reassessing differences. Am J Prev Med. 1996;12:327-37.
4. Chang SW, Kerlikowske K, Napoles-Springer A, Posner SF, Sickles EA, Perez-Stable EJ. Racial differences in timeliness of follow-up after abnormal screening mammography. Cancer. 1996;78:1395-402.
5. Rakowski W, Breen N, Meissner H, et al. Prevalence and correlates of repeat mammography among women aged 55-79 in the Year 2000 National Health Interview Survey. Prev Med. 2004;39:1-10.
6. Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. The association of ambulatory care with breast cancer stage at diagnosis among Medicare beneficiaries. J Gen Intern Med. 2005;20:38-44.
7. Roetzheim RG, Pal N, Tennant C, et al. Effects of health insurance and race on early detection of cancer. J Natl Cancer Inst. 1999;91:1409-15.
8. Elmore JG, Nakano CY, Linden HM, Reisch LM, Ayanian JZ, Larson EB. Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment. Med Care. 2005;43:141-8.
9. Ayanian JZ, Guadagnoli E. Variations in breast cancer treatment by patient and provider characteristics. Breast Cancer Res Treat. 1996;40:65-74.
10. Payne R, Medina E, Hampton JW. Quality of life concerns in patients with breast cancer: evidence for disparity of outcomes and experiences in pain management and palliative care among African-American women. Cancer. 2003;97:311-7.
11. Joslyn SA. Racial differences in treatment and survival from early-stage breast carcinoma. Cancer. 2002;95:1759-66.
12. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163:49-56.
13. Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003;97:134-47.
14. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334-57.
15. Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138:90-7.
16. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19:1455-61.
17. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat. 2003;81:21-31.
18. Gordon NH. Socioeconomic factors and breast cancer in black and white Americans. Cancer Metastasis Rev. 2003;22:55-65.
19. Brawley OW. Disaggregating the effects of race and poverty on breast cancer outcomes. J Natl Cancer Inst. 2002;94:471-3.
20. Chu KC, Tarone RE, Brawley OW. Breast cancer trends of black women compared with white women. Arch Fam Med. 1999;8:521-8.
21. Newman LA, Mason J, Cote D, et al. African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. Cancer. 2002;94:2844-54.
22. Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M. Trends in breast cancer by race and ethnicity. CA Cancer J Clin. 2003;53:342-55.
23. Russell A, Langlois T, Johnson G, Trentham-Dietz A, Remington P. Increasing gap in breast cancer mortality between black and white women. World Med J. 1999;98:37-9.
24. Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993;329:326-31.
25. Smedley BD, Stih AY, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: The National Academies Press; 2003.
26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.
27. Peele PB, Siminoff LA, Xu Y, Ravdin PM. Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information. Med Decision Making. 2005;25:301-7.
28. Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:82-134.
29. Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 3 - Estimating probabilities and utilities. Med Decision Making. 1997;17:136-41.
30. vonNeumann J, Morgenstern O. Theory of Games and Economic Behavior. Princeton, NJ: Princeton University Press; 1944.
31. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18:3302-17.
32. Jansen SJ, Kievit J, Nooij MA, et al. Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer. 2001;84:1577-85.
33. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003;83:803-19.
34. Dow KH, Lafferty P. Quality of life, survivorship, and psychosocial adjustment of young women with breast cancer after breast-conserving surgery and radiation therapy. Oncol Nurs Forum. 2000;27:1555-64.
35. Dow KH, Ferrell BR, Leigh S, Ly J, Gulasekaram P. An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat. 1996;39:261-73.
36. Ferrell BR, Grant MM, Funk BM, Otis-Green SA, Garcia NJ. Quality of life in breast cancer survivors: implications for developing support services. Oncol Nurs Forum. 1998;25:887-95.
37. Mast ME. Survivors of breast cancer: illness uncertainty, positive reappraisal, and emotional distress. Oncol Nurs Forum. 1998;25:555-62.
38. Kennedy ED, Detsky AS, Llewellyn-Thomas HA, et al. Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn's disease. Med Decision Making. 2000;20:72-8.
39. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-86.
40. Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien BJ. Are health states "timeless"? The case of the standard gamble method. J Clin Epidemiol. 1999;52:1047-53.
41. Franic DM, Pathak DS, Gafni A. Are health states "timeless"? A case study of an acute condition: post-chemotherapy nausea and vomiting. J Eval Clin Pract. 2003;9:69-82.
42. Fortin JM, Hirota LK, Bond BE, O'Connor AM, Col NF. Identifying patient preferences for communicating risk estimates: a descriptive pilot study. BMC Med Inform Decision Making. 2001;1:2.
43. Torrance G. Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Econom Planning Sci. 1976;10:129-36.
44. Torrance G, Thomas W, Sacket D. A utility maximization model for evaluation of health care programs. Health Serv Res. 1972;7:118-33.
45. Torrance G. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1-30.
46. Llewellyn-Thomas H, Sutherland HJ, Tibshirani R, Ciampi A, Till JE, Boyd NF. The measurement of patients' values in medicine. Med Decision Making. 1982;2:449-62.
47. Redelmeier DA, Heller DN. Time preference in medical decision making and cost-effectiveness analysis. Med Decision Making. 1993;13:212-7.
48. Hoyert D, Arias E, Smith B, Murphy S, Kochanek M. Deaths: final data for 1999. Natl Vital Stat Rep. 2001;49.
49. Cykert S, Phifer N. Surgical decisions for early stage, non-small cell lung cancer: which racially sensitive perceptions of cancer are likely to explain racial variation in surgery? Med Decision Making. 2003;23:167-76.
50. Bruner DW, Hanlon A, Mazzoni S, et al. Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:34-42.
51. Knight SJ, Siston AK, Chmiel JS, et al. Ethnic variation in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans. Clin Prostate Cancer. 2004;3:31-7.
52. Tsevat J. What do utilities measure? Med Care. 2000;38:160-164.
53. Feeny DH, Torrance GW. Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples. Med Care. 1989;27:S190-204.
54. Bleichrodt H, Johannesson M. The validity of QALYs: an experimental test of constant proportional tradeoff and utility independence. Med Decision Making. 1997;17:21-32.
55. Bleichrodt H, van Rijn J, Johannesson M. Probability weighting and utility curvature in QALY-based decision making. J Math Psychol. 1999;43:238-60.
56. NCI. Surveillance Epidemiology and End Results (SEER). Cancer Statistics. Available at: http://seer.cancer.gov/. Accessed August 30, 2005.